JLE

Epileptic Disorders

MENU

Response to lacosamide monotherapy in a patient with medically refractory Jeavons syndrome: a case report and review of the literature Volume 22, issue 5, October 2020

TEST YOURSELF

(1) What is the mechanism of action of lacosamide?

 

(2) What are the three characteristic features of Jeavons syndrome?

 

(3) What are some of the common treatment options used in Jeavons syndrome patients?

 

 

 

 

 

 

 

 

 

 

 

 

See answers

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Answers

(1) Lacosamide exerts its action by selectively enhancing slow inactivation of the sodium channel.

 

(2) Jeavons syndrome is characterized by: (i) eyelid myoclonia (hallmark) with or without brief absences; (ii) eye closure-induced seizures or electroencephalographic (EEG) paroxysms (brief generalized polyspikes and/or generalized spike-wave activity at 3-6 Hz, elicited by eyelid closure which may disappear in the dark); (iii) photosensitivity or photoparoxysmal response (eyelid myoclonia provoked by photic stimulation which may disappear when eyes are closed in total darkness)

 

(3) Valproic acid, lamotrigine, ethosuximide, levetiracetam, phenobarbital and benzodiazepines are commonly used with inconsistent efficacy, with drug-resistant cases requiring combination therapy. Lens therapy may also be used.

 

 

 

 

 Back to questions